Literature DB >> 28366750

Long-Term Outcome After Conservative Treatment and Direct Bypass Surgery of Moyamoya Disease at Late Suzuki Stage.

Peicong Ge1, Qian Zhang1, Xun Ye1, Xingju Liu1, Xiaofeng Deng1, Hao Li1, Rong Wang1, Yan Zhang1, Dong Zhang1, Jizong Zhao2.   

Abstract

OBJECTIVE: To investigate the long-term outcomes after conservative and direct surgical treatment for patients with moyamoya disease (MMD) at late Suzuki stage.
METHODS: We retrospectively reviewed 82 patients (164 hemispheres) with MMD at late Suzuki stage at Beijing Tiantan Hospital. Clinical features, radiologic findings, and outcomes were analyzed.
RESULTS: The mean age at diagnosis was 36.4 ± 11.7 years. The distribution of the initial Suzuki stage of MMD was as follows: stage 4, n = 113; stage 5, n = 45; stage 6, n = 6, posterior cerebral artery involvement was observed in 41 hemispheres (25.0%). The incidence of postoperative stroke (<48 hours) was 6.7%. During the average follow-up of 55.1 ± 16.2 months, including postoperative and follow-up strokes, 7 of 75 conservatively treated hemispheres (9.3%) and 9 of 89 surgically treated patients (10.1%) experienced a stroke event; there was no statistical significance in the Kaplan-Meier curve of stroke incidence between the surgical group and conservative group (log-rank test, P = 0.848). However, the rate of perfusion improvement in direct bypass surgically treated patients was higher than in those conservatively treated patients 3 months after discharge (P < 0.05).
CONCLUSIONS: Although direct bypass surgery was shown to effectively improve the cerebral perfusion in patients with MMD at late Suzuki stage, compared with conservative treatment, it did not reduce the risk of recurrent stroke. Further study is needed to determine whether direct bypass surgery is effective in patients with MMD at late Suzuki stage.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Conservative treatment; Direct bypass surgery; Late Suzuki stage; Moyamoya disease; Stroke

Mesh:

Year:  2017        PMID: 28366750     DOI: 10.1016/j.wneu.2017.03.101

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  6 in total

1.  Postoperative stroke and neurological outcomes in the early phase after revascularization surgeries for moyamoya disease: an age-stratified comparative analysis.

Authors:  Yoshio Araki; Kinya Yokoyama; Kenji Uda; Fumiaki Kanamori; Michihiro Kurimoto; Yoshiki Shiba; Takashi Mamiya; Masahiro Nishihori; Takashi Izumi; Masaki Sumitomo; Sho Okamoto; Kota Matsui; Ryo Emoto; Toshihiko Wakabayashi; Shigeyuki Matsui; Atsushi Natsume
Journal:  Neurosurg Rev       Date:  2021-01-08       Impact factor: 3.042

Review 2.  Surgical Treatment of Adult Moyamoya Disease.

Authors:  Si Un Lee; Chang Wan Oh; O-Ki Kwon; Jae Seung Bang; Seung Pil Ban; Hyoung Soo Byoun; Tackeun Kim
Journal:  Curr Treat Options Neurol       Date:  2018-05-28       Impact factor: 3.598

3.  Efficacy of STA-MCA bypass surgery in moyamoya angiopathy: long-term follow-up of the Caucasian Krupp Hospital cohort with 81 procedures.

Authors:  Markus Kraemer; Rusen Karakaya; Toshinori Matsushige; Jonas Graf; Philipp Albrecht; Hans-Peter Hartung; Peter Berlit; Rudolf Laumer; Frank Diesner
Journal:  J Neurol       Date:  2018-08-28       Impact factor: 4.849

4.  Surgical revascularization vs. conservative treatment for adult hemorrhagic moyamoya disease: analysis of rebleeding in 322 consecutive patients.

Authors:  Shaojie Yu; Nan Zhang; Jian Liu; Changwen Li; Sheng Qian; Yong Xu; Tao Yang; Nan Li; Minghui Zeng; Dongxue Li; Chengyu Xia
Journal:  Neurosurg Rev       Date:  2021-12-03       Impact factor: 3.042

5.  Predictors of preoperative cognitive dysfunction in adults with Moyamoya disease: a preliminary research.

Authors:  Jian Sun; Zhiyong Shi; Lebao Yu; Yujie Wen; Dong Zhang
Journal:  BMC Neurol       Date:  2022-01-06       Impact factor: 2.474

Review 6.  A critical appraisal of bypass surgery in moyamoya disease.

Authors:  Michael Moussouttas; Igor Rybinnik
Journal:  Ther Adv Neurol Disord       Date:  2020-05-26       Impact factor: 6.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.